The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index, and 1 are not checked yet.
Clinical research challenges posed by difficult-to-treat depression.
Open accessAbstract
Approximately one-third of individuals in a major depressive episode will not achieve sustained remission despite multiple, well-delivered treatments. These patients experience prolonged suffering and disproportionately utilize mental and general health care resources. The recently proposed clinical heuristic of ‘difficult-to-treat depression’ (DTD) aims to broaden our understanding and focus attention on the identification, clinical management, treatment selection, and outcomes of such individuals. Clinical trial methodologies developed to detect short-term therapeutic effects in treatment-responsive populations may not be appropriate in DTD. This report reviews three essential challenges for clinical intervention research in DTD: (1) how to define and subtype this heterogeneous group of patients; (2) how, when, and by what methods to select, acquire, compile, and interpret clinically meaningful outcome metrics; and (3) how to choose among alternative clinical trial design options to promote causal inference and generalizability. The boundaries of DTD are uncertain, and an evidence-based taxonomy and reliable assessment tools are preconditions for clinical research and subtyping. Traditional outcome metrics in treatment-responsive depression may not apply to DTD, as they largely reflect the only short-term symptomatic change and do not incorporate durability of benefit, side effect burden, or sustained impact on quality of life or daily function. The trial methodology will also require modification as trials will likely be of longer duration to examine the sustained impact, raising complex issues regarding control group selection, blinding and its integrity, and concomitant treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Instead, DTD is agnostic and rep resents a patient- centered and pragmatic ap proach to identifying therapeutic targets 84 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [84]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compelling case is made that TRD is potentially judgmental insofar as it may be interpreted as blaming the patient.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hollon, S. D., DeRubeis, R. J., Fawcett, J., Amsterdam, J. D., Shelton, R. C., Zajecka, J., Young, P. R., & Gallop, R. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1054 · Cited by 179 · cited 1×
“…the administration of sequential monotherapies and treatment combinations delivered in a ‘ try and try again ’ approach typically results in diminishing returns and may seem futile to the clinician and patient (DeRubeis et al., 2020; Dunner et al., 2006; Hollon et al., 2014; Rush et al., 2006b).”
Self-citationRetractedRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 11×
“Indeed, our understanding of the nat-ural history of mood disorders, the phases of illness, and the phases of treatment (e.g. continuation or maintenance regimens) may not readily apply to DTD (Frank et al., 1991; Rush et al., 2006a).”
InfluentialSelf-citationWang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695 · cited 1×
“…in high health costs that often persist for years (Amos et al., 2018; Benson, Szukis, Sheehan, Alphs, & Yuce, 2020; Greenberg, Corey-Lisle, Birnbaum, Marynchenko, & Claxton, 2004; Olfson, Amos, Benson, McRae, & Marcus, 2018; Sussman, O ’ Sullivan, Shah, Olfson, & Menzin, 2019; Wang et al., 2005).”
Mediators and Mechanisms of Change in Psychotherapy Research
Kazdin, A. E. (2007) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091432 · Cited by 2,504 · cited 1×
“…predictors based on moderator analyses); (2) estimating the likelihood of benefit of a single treatment (based on baseline features, i.e. prognostic predictors); and (3) identifying mediators of treatment outcome [i.e. processes deemed to be essential to achieving the benefit (Kazdin, 2007)].”
Fiske, A., Wetherell, J. L., & Gatz, M. (2009) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.032408.153621 · Cited by 2,353 · cited 1×
“Older depressed persons show a consistent tendency to under self-report symptom severity relative to observer measures (Fiske, Wetherell, & Gatz, 2009; Gallo, Anthony, & Muthén, 1994).”
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 2×
“Indeed, our understanding of the nat-ural history of mood disorders, the phases of illness, and the phases of treatment (e.g. continuation or maintenance regimens) may not readily apply to DTD (Frank et al., 1991; Rush et al., 2006a).”
O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910 · cited 1×
“…often cap the number of failed prior treatment trials or the duration of the current episode precisely because greater treatment resistance or chronicity is expected to negatively impact therapeutic outcomes, limiting detection of a therapeutic signal (O ’ Reardon et al., 2007; Rush et al., 2005).”
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Tunis, S., Bergel, E., Harvey, I., Magid, D. J., et al. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.12.011 · Cited by 1,389
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016) · Biomarker Insights · doi:10.4137/bmi.s38440 · Cited by 1,381 · cited 1×
“It informs management decisions, and assessment of disease outcomes and complications (Sherwani, Khan, Ekhzaimy, Masood, & Sakharkar, 2016).”
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 3×
“…treatments is not specified (e.g. two selective serotonin reuptake inhibitors (SSRIs) v. one SSRI followed by transcranial magnetic stimulation) (Fava, 2003b; Fekadu et al., 2009), and it is unlikely that all treatments are equivalent in their prognostic implications for insufficient or…”
Research works printed but not linked: 3
- Hofer, 2012, Handbook of developmental research methods, 3
- Thase, 1995, Psychopharmacology: The fourth generation of progress, 1081
- 2011, Nonpharmacologic interventions for treatment-resistant depression in adults (comparative effectiveness review number 33)
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationSingle-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.14530 · Cited by 545
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 130
Domschke, K., Seuling, P. D., Schiele, M. A., Bandelow, B., Batelaan, N. M., Bokma, W. A., Branchi, I., Broich, K., Burkauskas, J., Davies, S. J. C., et al. (2024) · World Psychiatry · doi:10.1002/wps.21177 · Cited by 46
“However, the boundaries of “difficulttotreat” AD are uncertain, and an evidencebased taxonomy as well as reliable assessment tools beyond traditional outcome metrics remain to be established for this condition 89 .”
Strawn, J. R., Mills, J. A., Suresh, V., Mayes, T. L., Gentry, M. T., Trivedi, M. H., & Croarkin, P. E. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.01.043 · Cited by 50
Metadata
- Authors
- Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., & McAllister-Williams, R. H.
- Affiliations
- Texas Tech University (US)
- Columbia University (US)
- Washington University in St. Louis (US)
- LivaNova (United States) (US)
- Vanderbilt University (US)
- KU Leuven (BE)
- King's College London (GB)
- Sheppard and Enoch Pratt Hospital (US)
- Heinrich Heine University Düsseldorf (DE)
- University of Pennsylvania (US)
- Cumbria Northumberland Tyne and Wear NHS Foundation Trust (GB)
- Corresponding author
- Rush, A. John
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2022-01-07
- Volume
- 52
- Issue
- 3
- Pages
- 419-432
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- PMC
- PMC8883824
- OpenAlex
- W4205450793
- Semantic Scholar
- 909420869c621e75872adb16ddaab0d4cb0b22f8
- Cited by
- 89
- References
- 105
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 17 · 2023: 21 · 2022: 9
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Psychological Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Patient-Centered Outcomes Research Institute
- Stanley Medical Research Institute
- Foundation for Barnes-Jewish Hospital
- University of Texas Southwestern Medical Center
- Sunovion
- Jazz Pharmaceuticals
- LivaNova
- Neurocrine Biosciences
- Sage Therapeutics
- Assurex Health
- National Institute for Health and Care Research (NIHR202380)
- University of Oxford
- Otsuka Pharmaceutical
- European College of Neuropsychopharmacology
- Servier
- H. Lundbeck A/S
- Allergan
- National Institute of Mental Health
- Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- difficult-to-treat depression, treatment-resistant depression, major depressive disorder, clinical trial design, outcome measures, patient subtyping, quality of life, blinding, control group selection, concomitant treatment, causal inference
- MeSH terms
- Depression, Major Depressive Disorder, Humans, Quality of Life, Treatment Outcome, Uncertainty
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical research challenges posed by difficult-to-treat depression. https://app.cochat.ai/papers/10.1017/s0033291721004943
- The paper
- Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., & McAllister-Williams, R. H. (2022). Clinical research challenges posed by difficult-to-treat depression. Psychological Medicine. https://doi.org/10.1017/s0033291721004943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.